876-P: Effectiveness and Tolerability of Intensification of Canagliflozin Dose from 100 mg to 300 mg Daily In Patients with Type 2 Diabetes in Real Life—The INTENSIFY Study
There is a paucity of data evaluating the strategy of intensification of canagliflozin therapy by increasing the dose from canagliflozin 100 mg/d (CANA100) to canagliflozin 300 mg/d (CANA300), since all clinical trials compared both doses separately. The aim of this multicentric study was to assess...
Gespeichert in:
| Veröffentlicht in: | Diabetes (New York, N.Y.) N.Y.), 2023-06, Vol.72 (Supplement_1), p.1 |
|---|---|
| Hauptverfasser: | , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | |
|---|---|
| container_issue | Supplement_1 |
| container_start_page | 1 |
| container_title | Diabetes (New York, N.Y.) |
| container_volume | 72 |
| creator | GORGOJO-MARTINEZ, JUAN J. FERREIRA-OCAMPO, PABLO J. GALDON-SANZ PASTOR, ALBA CÁRDENAS-SALAS, JERSY J. ANTÓN-BRAVO, TERESA BRITO, MIGUEL ALMODOVAR-RUIZ, FRANCISCA |
| description | There is a paucity of data evaluating the strategy of intensification of canagliflozin therapy by increasing the dose from canagliflozin 100 mg/d (CANA100) to canagliflozin 300 mg/d (CANA300), since all clinical trials compared both doses separately. The aim of this multicentric study was to assess in real life the effectiveness and tolerability of the intensification of canagliflozin to 300 mg/d in patients with T2DM and suboptimal metabolic control with CANA100. The primary outcome variables were changes in A1c and weight at the end of the follow-up. 317 patients met the inclusion criteria (age 62.2 years, A1c 7.55%, weight 88.6 kg). Median time of treatment with CANA300 was 20.8 months. Switching to CANA300 induced a significant decrease in A1c (-0.47%) and weight (-2.9 kg), both p |
| doi_str_mv | 10.2337/db23-876-P |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_journals_2849358491</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2849358491</sourcerecordid><originalsourceid>FETCH-LOGICAL-c631-99d7166256df84610e26758aa33de588cdf7e3b16be269930f322705e98d3f203</originalsourceid><addsrcrecordid>eNotUc1uEzEQtqoikRYuPMFIvVXa4p-uveaGkhQiRSWie4DTyrs7bl1t7HTttFpOPATPwUPxJDgEjTQzmvm-b6T5CHnH6BUXQr3vWy6KSslic0JmTAtdCK6-nZIZpYwXTGn1mpzF-EgplTlm5Pc_8AdYWotdcs_oMUYwvoc6DDia1g0uTRAsrHxCH511nUku-MNobry5H5wdwg_nYREigh3DFhilsL2HFEAcu4Vxw5QVYJO56FOEF5ceoJ52CBwWzrSYMEIW-YpmgLWz-Ofnr_oBYXVbL2_vVjff4S7t--kNeWXNEPHt_3pO6ptlPf9crL98Ws0_rotOClZo3SsmJS9lb6tryShyqcrKGCF6LKuq661C0TLZ5oXWglrBuaIl6qoXllNxTi6OsrsxPO0xpuYx7EefLza8utaizIll1OUR1Y0hxhFtsxvd1oxTw2hzsKM52NHkDzcb8RcLonvw</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2849358491</pqid></control><display><type>article</type><title>876-P: Effectiveness and Tolerability of Intensification of Canagliflozin Dose from 100 mg to 300 mg Daily In Patients with Type 2 Diabetes in Real Life—The INTENSIFY Study</title><source>Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals</source><source>PubMed Central</source><creator>GORGOJO-MARTINEZ, JUAN J. ; FERREIRA-OCAMPO, PABLO J. ; GALDON-SANZ PASTOR, ALBA ; CÁRDENAS-SALAS, JERSY J. ; ANTÓN-BRAVO, TERESA ; BRITO, MIGUEL ; ALMODOVAR-RUIZ, FRANCISCA</creator><creatorcontrib>GORGOJO-MARTINEZ, JUAN J. ; FERREIRA-OCAMPO, PABLO J. ; GALDON-SANZ PASTOR, ALBA ; CÁRDENAS-SALAS, JERSY J. ; ANTÓN-BRAVO, TERESA ; BRITO, MIGUEL ; ALMODOVAR-RUIZ, FRANCISCA</creatorcontrib><description><![CDATA[There is a paucity of data evaluating the strategy of intensification of canagliflozin therapy by increasing the dose from canagliflozin 100 mg/d (CANA100) to canagliflozin 300 mg/d (CANA300), since all clinical trials compared both doses separately. The aim of this multicentric study was to assess in real life the effectiveness and tolerability of the intensification of canagliflozin to 300 mg/d in patients with T2DM and suboptimal metabolic control with CANA100. The primary outcome variables were changes in A1c and weight at the end of the follow-up. 317 patients met the inclusion criteria (age 62.2 years, A1c 7.55%, weight 88.6 kg). Median time of treatment with CANA300 was 20.8 months. Switching to CANA300 induced a significant decrease in A1c (-0.47%) and weight (-2.9 kg), both p<0.0001. The percentage of patients with A1c <7% increased significantly from 26.7% with CANA100 to 51.6% with CANA300 (p<0.0001). In those individuals with poor glycemic control (A1c >8%, mean 9.0%), A1c was significantly reduced by -1.24% (p<0.0001). There were significant improvements in FPG (-14.8 mg/dl), SBP (-5.3 mmHg) and DBP (-3,1 mmHg), all p<0.05. Serum liver enzymes and albuminuria also decreased significantly. Considering the entire treatment period (initial treatment with CANA100 and later switch to CANA300), with a median follow-up of 38.8 months, patients achieved a statistically significant overall reduction in A1c (-1.30%), weight (-5.8 kg), SBP (-9.6 mmHg) and DBP (-4.7 mmHg), all p<0.0001. 7.9% of patients discontinued CANA300; the most frequent causes of withdrawals were genital mycotic infections (1.9%) and urinary tract infections (0.9%).
In summary, intensification of canagliflozin therapy to CANA300 achieved further significant and clinically relevant reductions in A1c, weight, and BP in patients with T2DM. The effectiveness of the switch was particularly relevant in those patients with higher A1c levels.]]></description><identifier>ISSN: 0012-1797</identifier><identifier>EISSN: 1939-327X</identifier><identifier>DOI: 10.2337/db23-876-P</identifier><language>eng</language><publisher>New York: American Diabetes Association</publisher><subject>Antidiabetics ; Clinical trials ; Diabetes ; Diabetes mellitus (non-insulin dependent) ; Patients ; Statistical analysis ; Urinary tract ; Weight</subject><ispartof>Diabetes (New York, N.Y.), 2023-06, Vol.72 (Supplement_1), p.1</ispartof><rights>Copyright American Diabetes Association Jun 2023</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,778,782,27907,27908</link.rule.ids></links><search><creatorcontrib>GORGOJO-MARTINEZ, JUAN J.</creatorcontrib><creatorcontrib>FERREIRA-OCAMPO, PABLO J.</creatorcontrib><creatorcontrib>GALDON-SANZ PASTOR, ALBA</creatorcontrib><creatorcontrib>CÁRDENAS-SALAS, JERSY J.</creatorcontrib><creatorcontrib>ANTÓN-BRAVO, TERESA</creatorcontrib><creatorcontrib>BRITO, MIGUEL</creatorcontrib><creatorcontrib>ALMODOVAR-RUIZ, FRANCISCA</creatorcontrib><title>876-P: Effectiveness and Tolerability of Intensification of Canagliflozin Dose from 100 mg to 300 mg Daily In Patients with Type 2 Diabetes in Real Life—The INTENSIFY Study</title><title>Diabetes (New York, N.Y.)</title><description><![CDATA[There is a paucity of data evaluating the strategy of intensification of canagliflozin therapy by increasing the dose from canagliflozin 100 mg/d (CANA100) to canagliflozin 300 mg/d (CANA300), since all clinical trials compared both doses separately. The aim of this multicentric study was to assess in real life the effectiveness and tolerability of the intensification of canagliflozin to 300 mg/d in patients with T2DM and suboptimal metabolic control with CANA100. The primary outcome variables were changes in A1c and weight at the end of the follow-up. 317 patients met the inclusion criteria (age 62.2 years, A1c 7.55%, weight 88.6 kg). Median time of treatment with CANA300 was 20.8 months. Switching to CANA300 induced a significant decrease in A1c (-0.47%) and weight (-2.9 kg), both p<0.0001. The percentage of patients with A1c <7% increased significantly from 26.7% with CANA100 to 51.6% with CANA300 (p<0.0001). In those individuals with poor glycemic control (A1c >8%, mean 9.0%), A1c was significantly reduced by -1.24% (p<0.0001). There were significant improvements in FPG (-14.8 mg/dl), SBP (-5.3 mmHg) and DBP (-3,1 mmHg), all p<0.05. Serum liver enzymes and albuminuria also decreased significantly. Considering the entire treatment period (initial treatment with CANA100 and later switch to CANA300), with a median follow-up of 38.8 months, patients achieved a statistically significant overall reduction in A1c (-1.30%), weight (-5.8 kg), SBP (-9.6 mmHg) and DBP (-4.7 mmHg), all p<0.0001. 7.9% of patients discontinued CANA300; the most frequent causes of withdrawals were genital mycotic infections (1.9%) and urinary tract infections (0.9%).
In summary, intensification of canagliflozin therapy to CANA300 achieved further significant and clinically relevant reductions in A1c, weight, and BP in patients with T2DM. The effectiveness of the switch was particularly relevant in those patients with higher A1c levels.]]></description><subject>Antidiabetics</subject><subject>Clinical trials</subject><subject>Diabetes</subject><subject>Diabetes mellitus (non-insulin dependent)</subject><subject>Patients</subject><subject>Statistical analysis</subject><subject>Urinary tract</subject><subject>Weight</subject><issn>0012-1797</issn><issn>1939-327X</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2023</creationdate><recordtype>article</recordtype><recordid>eNotUc1uEzEQtqoikRYuPMFIvVXa4p-uveaGkhQiRSWie4DTyrs7bl1t7HTttFpOPATPwUPxJDgEjTQzmvm-b6T5CHnH6BUXQr3vWy6KSslic0JmTAtdCK6-nZIZpYwXTGn1mpzF-EgplTlm5Pc_8AdYWotdcs_oMUYwvoc6DDia1g0uTRAsrHxCH511nUku-MNobry5H5wdwg_nYREigh3DFhilsL2HFEAcu4Vxw5QVYJO56FOEF5ceoJ52CBwWzrSYMEIW-YpmgLWz-Ofnr_oBYXVbL2_vVjff4S7t--kNeWXNEPHt_3pO6ptlPf9crL98Ws0_rotOClZo3SsmJS9lb6tryShyqcrKGCF6LKuq661C0TLZ5oXWglrBuaIl6qoXllNxTi6OsrsxPO0xpuYx7EefLza8utaizIll1OUR1Y0hxhFtsxvd1oxTw2hzsKM52NHkDzcb8RcLonvw</recordid><startdate>20230620</startdate><enddate>20230620</enddate><creator>GORGOJO-MARTINEZ, JUAN J.</creator><creator>FERREIRA-OCAMPO, PABLO J.</creator><creator>GALDON-SANZ PASTOR, ALBA</creator><creator>CÁRDENAS-SALAS, JERSY J.</creator><creator>ANTÓN-BRAVO, TERESA</creator><creator>BRITO, MIGUEL</creator><creator>ALMODOVAR-RUIZ, FRANCISCA</creator><general>American Diabetes Association</general><scope>AAYXX</scope><scope>CITATION</scope><scope>K9.</scope><scope>NAPCQ</scope></search><sort><creationdate>20230620</creationdate><title>876-P: Effectiveness and Tolerability of Intensification of Canagliflozin Dose from 100 mg to 300 mg Daily In Patients with Type 2 Diabetes in Real Life—The INTENSIFY Study</title><author>GORGOJO-MARTINEZ, JUAN J. ; FERREIRA-OCAMPO, PABLO J. ; GALDON-SANZ PASTOR, ALBA ; CÁRDENAS-SALAS, JERSY J. ; ANTÓN-BRAVO, TERESA ; BRITO, MIGUEL ; ALMODOVAR-RUIZ, FRANCISCA</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c631-99d7166256df84610e26758aa33de588cdf7e3b16be269930f322705e98d3f203</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2023</creationdate><topic>Antidiabetics</topic><topic>Clinical trials</topic><topic>Diabetes</topic><topic>Diabetes mellitus (non-insulin dependent)</topic><topic>Patients</topic><topic>Statistical analysis</topic><topic>Urinary tract</topic><topic>Weight</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>GORGOJO-MARTINEZ, JUAN J.</creatorcontrib><creatorcontrib>FERREIRA-OCAMPO, PABLO J.</creatorcontrib><creatorcontrib>GALDON-SANZ PASTOR, ALBA</creatorcontrib><creatorcontrib>CÁRDENAS-SALAS, JERSY J.</creatorcontrib><creatorcontrib>ANTÓN-BRAVO, TERESA</creatorcontrib><creatorcontrib>BRITO, MIGUEL</creatorcontrib><creatorcontrib>ALMODOVAR-RUIZ, FRANCISCA</creatorcontrib><collection>CrossRef</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Nursing & Allied Health Premium</collection><jtitle>Diabetes (New York, N.Y.)</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>GORGOJO-MARTINEZ, JUAN J.</au><au>FERREIRA-OCAMPO, PABLO J.</au><au>GALDON-SANZ PASTOR, ALBA</au><au>CÁRDENAS-SALAS, JERSY J.</au><au>ANTÓN-BRAVO, TERESA</au><au>BRITO, MIGUEL</au><au>ALMODOVAR-RUIZ, FRANCISCA</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>876-P: Effectiveness and Tolerability of Intensification of Canagliflozin Dose from 100 mg to 300 mg Daily In Patients with Type 2 Diabetes in Real Life—The INTENSIFY Study</atitle><jtitle>Diabetes (New York, N.Y.)</jtitle><date>2023-06-20</date><risdate>2023</risdate><volume>72</volume><issue>Supplement_1</issue><spage>1</spage><pages>1-</pages><issn>0012-1797</issn><eissn>1939-327X</eissn><abstract><![CDATA[There is a paucity of data evaluating the strategy of intensification of canagliflozin therapy by increasing the dose from canagliflozin 100 mg/d (CANA100) to canagliflozin 300 mg/d (CANA300), since all clinical trials compared both doses separately. The aim of this multicentric study was to assess in real life the effectiveness and tolerability of the intensification of canagliflozin to 300 mg/d in patients with T2DM and suboptimal metabolic control with CANA100. The primary outcome variables were changes in A1c and weight at the end of the follow-up. 317 patients met the inclusion criteria (age 62.2 years, A1c 7.55%, weight 88.6 kg). Median time of treatment with CANA300 was 20.8 months. Switching to CANA300 induced a significant decrease in A1c (-0.47%) and weight (-2.9 kg), both p<0.0001. The percentage of patients with A1c <7% increased significantly from 26.7% with CANA100 to 51.6% with CANA300 (p<0.0001). In those individuals with poor glycemic control (A1c >8%, mean 9.0%), A1c was significantly reduced by -1.24% (p<0.0001). There were significant improvements in FPG (-14.8 mg/dl), SBP (-5.3 mmHg) and DBP (-3,1 mmHg), all p<0.05. Serum liver enzymes and albuminuria also decreased significantly. Considering the entire treatment period (initial treatment with CANA100 and later switch to CANA300), with a median follow-up of 38.8 months, patients achieved a statistically significant overall reduction in A1c (-1.30%), weight (-5.8 kg), SBP (-9.6 mmHg) and DBP (-4.7 mmHg), all p<0.0001. 7.9% of patients discontinued CANA300; the most frequent causes of withdrawals were genital mycotic infections (1.9%) and urinary tract infections (0.9%).
In summary, intensification of canagliflozin therapy to CANA300 achieved further significant and clinically relevant reductions in A1c, weight, and BP in patients with T2DM. The effectiveness of the switch was particularly relevant in those patients with higher A1c levels.]]></abstract><cop>New York</cop><pub>American Diabetes Association</pub><doi>10.2337/db23-876-P</doi></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0012-1797 |
| ispartof | Diabetes (New York, N.Y.), 2023-06, Vol.72 (Supplement_1), p.1 |
| issn | 0012-1797 1939-327X |
| language | eng |
| recordid | cdi_proquest_journals_2849358491 |
| source | Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals; PubMed Central |
| subjects | Antidiabetics Clinical trials Diabetes Diabetes mellitus (non-insulin dependent) Patients Statistical analysis Urinary tract Weight |
| title | 876-P: Effectiveness and Tolerability of Intensification of Canagliflozin Dose from 100 mg to 300 mg Daily In Patients with Type 2 Diabetes in Real Life—The INTENSIFY Study |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-16T22%3A34%3A47IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=876-P:%20Effectiveness%20and%20Tolerability%20of%20Intensification%20of%20Canagliflozin%20Dose%20from%20100%20mg%20to%20300%20mg%20Daily%20In%20Patients%20with%20Type%202%20Diabetes%20in%20Real%20Life%E2%80%94The%20INTENSIFY%20Study&rft.jtitle=Diabetes%20(New%20York,%20N.Y.)&rft.au=GORGOJO-MARTINEZ,%20JUAN%20J.&rft.date=2023-06-20&rft.volume=72&rft.issue=Supplement_1&rft.spage=1&rft.pages=1-&rft.issn=0012-1797&rft.eissn=1939-327X&rft_id=info:doi/10.2337/db23-876-P&rft_dat=%3Cproquest_cross%3E2849358491%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2849358491&rft_id=info:pmid/&rfr_iscdi=true |